A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors

Published:2016-11-21 Issue:1 Volume:7 Page:102-113
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discov

Author:

Saura Cristina,Roda Desamparados,Roselló Susana,Oliveira Mafalda,Macarulla Teresa,Pérez-Fidalgo José Alejandro,Morales-Barrera Rafael,Sanchis-García Juan Manuel,Musib Luna,Budha Nageshwar,Zhu Jin,Nannini Michelle,Chan Wai Y.,Sanabria Bohórquez Sandra M.,Meng Raymond D.,Lin Kui,Yan Yibing,Patel Premal,Baselga José,Tabernero Josep,Cervantes Andrés

Funder

Genentech, Inc.

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 141 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The treatment landscape of triple-negative breast cancer;Medical Oncology;2024-08-29

2. Therapeutic Potential of Silver Nitroprusside Nanoparticles for Melanoma;ACS Applied Bio Materials;2024-08-08

3. The essential roles of lncRNAs/PI3K/AKT axis in gastrointestinal tumors;Frontiers in Cell and Developmental Biology;2024-08-05

4. Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: biomarkers and beyond;Critical Reviews in Oncology/Hematology;2024-08

5. Beyond Anti-PD-1/PD-L1: Improving Immune Checkpoint Inhibitor Responses in Triple-Negative Breast Cancer;Cancers;2024-06-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP